B. Esteves

Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC)

Pankaj Bhargava, B. Esteves, Dmitry Nosov et al. · Journal of Clinical Oncology · 2009 · 31 citations

Pathology, Preliminary Orr, Selective Vegfr1 +18

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma

Mayer Fishman, S. Srinivas, Ralph J. Hauke et al. · European Journal of Cancer · 2013 · 30 citations · Full text

Phase Ib Study, Urology, Medicine +5

Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

Pankaj Bhargava, B. Esteves, Mohammed Al-Adhami et al. · Journal of Clinical Oncology · 2010 · 24 citations

Surgical Oncology, Renal Pathology, Pharmacotherapy +19

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

Robert J. Motzer, D. Nosov, Tim Eisen et al. · European Urology Supplements · 2012 · 19 citations

Urology, Genitourinary Cancer, Medicine +7

A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC).

Robert J. Motzer, Pankaj Bhargava, B. Esteves et al. · Journal of Clinical Oncology · 2011 · 16 citations

Surgical Oncology, Pharmacotherapy, Pre-clinical Pharmacology +19